CERN Accelerating science

Hem > CERN Experiments > MEDICIS Internal Notes

MEDICIS Internal Notes

Sök i 39 journaler efter:
Söktips
Avancerad sökning
Add to Search +
Senast inlagda poster:
2024-07-01
07:55
Tb and Sc radionuclide separation and purification methods from solid targets and liquids for theranostic radiopharmaceutical development / Pajuste, Elina (University of Latvia (LV)) ; Mamis, Edgars (University of Latvia (LV)) ; Kalnina, Patricija (University of Latvia (LV))
There is a new radiochemistry lab being set up at the University of Latvia, dedicated to radionuclide studies with a particular interest in medical radionuclides. While the first studies with Sc isotopes are ongoing, the aim of the lab is to build competence also in radiolanthanides and alpha decay medical radionuclide purification and labeling studies. [...]
MED-039.- Geneva : CERN, 2024 - 2. Fulltext: DOCX;

Detaljerad journal - Similar records
2024-06-30
12:54
Pre-clinical proof-of-concept of a novel CCR5-targeted radioligand cancer therapy strategy / Garibotto, Valentina (HUG) ; Bejuy, O (HUG) ; Grotzky, Andrea (HUG) ; Montukur, G (UNIGE) ; Bois, Frederic (HUG) ; Hartley, O (UNIGE)
Triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC) are highly prevalent life- threatening diseases for which available treatment options are limited. Theranostic drugs use a ligand of a tumor cell molecular target in combination with different radiometals to both image and therapeutically target a tumor. [...]
MED-038.- Geneva : CERN, 2024 - 2. Fulltext: DOCX;

Detaljerad journal - Similar records
2023-12-03
23:21
AlphaMET (Metrology for Emerging Targeted Alpha Therapies) / Denis-Bacelar, Ana (NPL) ; Koole, Michel (KULeuven) ; Collins, Sean (NPL)
Targeted alpha therapy (TAT) is a rapidly growing cancer treatment modality, whereby alpha-emitting radiopharmaceuticals are combined with a targeting molecule to selectively seek tumours whilst minimising the damage to healthy cells. TAT is showing promising efficacy and increased survival in clinical trials for a variety of cancers; however, several unmet and unique measurement challenges remain a barrier to enable the safe and optimised implementation of emerging TATs. [...]
MED-037.- Geneva : CERN, 2023 - 3. Fulltext: DOC;

Detaljerad journal - Similar records
2023-12-03
23:13
Clinical and Pre-clinical Evaluation of Theranostic Pair (Terbium-161 and Terbium-155) for Imaging and Radionuclide Targeted Therapy of Tumors / Khan, Qaiser (PINSTECH)
The idea of theranostic approach is rapidly gaining momentum among the academia and practitioners in nuclear medicine community and there is considerable interest to commercially produce these isotopes for clinical applications. The approach combines diagnosis and therapy with suitable radiotracers [...]
MED-036.- Geneva : CERN, 2023 - 3. Fulltext: DOC;

Detaljerad journal - Similar records
2023-03-21
17:46
153SM-FAPI-46 RADIOLIGAND THERAPY WITH HIGH-MOLAR ACTIVITY 153SM / Prior, John (CHUV) ; Kratochwill, Clemens (Heidelberg University Hospital) ; Ooms, Marteen (SCK CEN) ; Cocolios, Thomas Elias (KU Leuven (BE)) ; Decristoforo, Clemens (INMUL)
New radiobioconjugates targeting fibroblast overexpressed in certain forms of cancers have recently been developed by the dept of nuclear medicine in Heidelberg and have shown important results in a range of different preclinical and clinical investigations. It demonstrates the potential of a new generation of radiopharmaceuticals targeting the Fibroblast Activation Protein (FAP), quinolone-based FAP inhibitors (FAPI) with a DOTA-chelator moiety and have shown potential benefits in both diagnosis and treatment, including patients presenting disseminated metastasis in lungs. [...]
MED-035.- Geneva : CERN, 2023 - 3. Fulltext: DOC;

Detaljerad journal - Similar records
2023-03-21
17:40
Determination of 227Ac impurity in 225Ac using alpha spectrometry / Cusnir, Ruslan (Centre Hospitalier Universitaire Lausanne CHUV (CH)) ; Bailat, Claude (CHUV) ; Straub, Marietta (Centre Hospitalier Universitaire Lausanne CHUV (CH))
225 Ac (actinium-225, t 1/2 = 9.9 days) is currently in the spotlight owing to its promising radiotherapeutic applications in nuclear medicine. This alpha-emitter can be produced using an accelerator, however this route involves the formation of an undesirable radionuclidic impurity of 227 Ac (actinium-227, t 1/2 = 21.8 years). [...]
MED-034.- Geneva : CERN, 2023 - 2. Fulltext: PDF;

Detaljerad journal - Similar records
2023-03-17
15:06
Dual Tumor Targeting Based on a pH Sensitive Peptide Platform / Campello, Maria Paula Cabral (C2TN) ; Paulo, Antonio (C2TN) ; Gano, Lurdes (C2TN) ; Fernandes, Celia (C2TN)
Nowadays it is well established that the microenvironment of solid tumors is associated with increased metabolic activity and hypoxia resulting in an elevated extracellular acidity. Acidosis is associated with tumor development both at very early and at advanced stages, being a tumor property that may serve as a general biomarker. [...]
MED-033.- Geneva : CERN, 2023 - 4. Fulltext: DOCX;

Detaljerad journal - Similar records
2021-11-07
23:57
PRISMAP – The European medical radionuclide programme: CERN-MEDICIS contribution / Stora, Thierry (CERN)
PRISMAP is the European medical radionuclide programme on the production of high purity radionuclides (radioactive isotopes) by mass separation (www.prismap.eu). We federate a European consortium of the key intense neutron sources, isotope mass separation facilities and high-power accelerators and cyclotrons, with leading biomedical and healthcare research institutes in the active translation of the emerging radionuclides into medical diagnosis and treatment. [...]
MED-032.- Geneva : CERN, 2021 - 2. Fulltext: DOC;

Detaljerad journal - Similar records
2021-03-01
19:20
Theranostics studies using 152/149Tb-labeled anti-CXCR4 probes in tumor mice / Cleeren, Frederik (KU Leuven)
The chemokine receptor CXCR4 is a seven transmembrane G protein-coupled receptor and is involved in various inflammatory and autoimmune diseases, as well as in cancer metastasis and progression. Binding of the endogenous ligand CXCL12 (also known as stromal cell-derived factor-1α (SDF-1α)) to CXCR4 leads to activation of downstream signaling pathways that exert critical functions in development (organogenesis), normal physiology as well in disease processes. [...]
MED-031.- Geneva : CERN, 2021 - 4. Fulltext: PDF;

Detaljerad journal - Similar records
2021-03-01
19:08
Targeted Alpha Therapy research in Belgium: qualifying the 225Ac pipeline / Cocolios, Thomas Elias (KU Leuven (BE)) ; Cleeren, Frederick (KU Leuven)
Targeted Alpha Therapy (TAT) is a very promising form of targeted radionuclide therapy thanks to the high linear energy transfer of the heavy alpha particles. The isotope 225Ac is particularly attractive as its relatively long half-life (T1/2=10 days) is appropriate for vector molecules with longer biological half-life (e.g. [...]
MED-030.- Geneva : CERN, 2021 - 4. Fulltext: 3.PDF;

Detaljerad journal - Similar records